ABVC Biopharma Inc
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II … Read more
ABVC Biopharma Inc (ABVC) - Total Liabilities
Latest total liabilities as of December 2025: $7.76 Million USD
Based on the latest financial reports, ABVC Biopharma Inc (ABVC) has total liabilities worth $7.76 Million USD as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
ABVC Biopharma Inc - Total Liabilities Trend (2002–2025)
This chart illustrates how ABVC Biopharma Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
ABVC Biopharma Inc Competitors by Total Liabilities
The table below lists competitors of ABVC Biopharma Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ulusoy Elektrik Imalat
IS:ULUSE
|
Turkey | TL6.04 Billion |
|
Crown Confectionery Co Ltd
KO:264900
|
Korea | ₩132.64 Billion |
|
Arena Group Holdings Inc
NYSE MKT:AREN
|
USA | $131.75 Million |
|
Adyton Resources Corporation
PINK:ADYRF
|
USA | $980.02K |
|
Yuyu Pharma Inc
KO:000227
|
Korea | ₩63.32 Billion |
|
Malaysian Bulk Carriers Bhd
KLSE:5077
|
Malaysia | RM149.61 Million |
|
CIFI Holdings (Group) Co. Ltd
F:6CI
|
Germany | €196.91 Billion |
|
Ebebek Magazacilik Anonim Sirketi
IS:EBEBK
|
Turkey | TL10.06 Billion |
Liability Composition Analysis (2002–2025)
This chart breaks down ABVC Biopharma Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.41 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.70 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.37 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ABVC Biopharma Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ABVC Biopharma Inc (2002–2025)
The table below shows the annual total liabilities of ABVC Biopharma Inc from 2002 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $7.76 Million | +13.92% |
| 2024-12-31 | $6.82 Million | +4.36% |
| 2023-12-31 | $6.53 Million | +2.96% |
| 2022-12-31 | $6.34 Million | +31.40% |
| 2021-12-31 | $4.83 Million | -46.03% |
| 2020-12-31 | $8.94 Million | +26.83% |
| 2019-12-31 | $7.05 Million | +20.65% |
| 2018-12-31 | $5.85 Million | +41.06% |
| 2017-12-31 | $4.14 Million | -36.62% |
| 2016-12-31 | $6.54 Million | +16600.13% |
| 2015-12-31 | $39.15K | +15.05% |
| 2014-12-31 | $34.03K | -98.14% |
| 2011-12-31 | $1.83 Million | -44.25% |
| 2010-12-31 | $3.29 Million | +30.01% |
| 2009-12-31 | $2.53 Million | -7.76% |
| 2008-12-31 | $2.74 Million | +200.02% |
| 2007-12-31 | $913.84K | +1622.04% |
| 2006-12-31 | $53.07K | +1849.56% |
| 2005-12-31 | $2.72K | -8.16% |
| 2004-12-31 | $2.96K | -90.12% |
| 2003-12-31 | $30.00K | 0.00% |
| 2002-12-31 | $30.00K | -- |